Gomi T, Ikeda T, Yuhara M, Sakurai J, Nakayama D, Ikegami F
Department of Nephrology, Kanto-Teishin Hospital, Tokyo, Japan.
J Hypertens. 1988 May;6(5):389-92.
The ratio of the plasma level of beta-thromboglobulin (beta-TG) to platelet factor 4 (PF-4) which is regarded as a most reliable indicator of platelet activation in vivo, was followed in 52 subjects at various stages of essential hypertension according to the WHO classification. These comprised 30 cases at stage I, 19 cases at stage II and three cases at stage III, and 20 age-matched normotensive control subjects. The observed beta-TG:PF-4 ratio in the hypertensive patients was 4.59 +/- 0.20, which was significantly higher than the value of 3.13 +/- 0.19 recorded in the normotensive control subjects. According to the WHO classification, beta-TG:PF-4 ratios in hypertensive patients at stages I, II and III were 3.93 +/- 0.19, 5.31 +/- 0.35 and 6.56 +/- 0.12, respectively. The beta-TG:PF-4 ratio revealed a tendency of platelet activation to increase with advanced progress of hypertensive vascular lesions. These results suggest that the abnormal platelet function observed in patients with essential hypertension plays an important role in the development of hypertensive vascular complications.
根据世界卫生组织(WHO)的分类标准,对52例处于原发性高血压不同阶段的患者,以及20例年龄匹配的血压正常对照者,跟踪检测了血浆β-血小板球蛋白(β-TG)水平与血小板第4因子(PF-4)水平的比值,该比值被视为体内血小板活化的最可靠指标。其中,I期患者30例,II期患者19例,III期患者3例。高血压患者中观察到的β-TG:PF-4比值为4.59±0.20,显著高于血压正常对照者记录的3.13±0.19的值。根据WHO分类,I期、II期和III期高血压患者的β-TG:PF-4比值分别为3.93±0.19、5.31±0.35和6.56±0.12。β-TG:PF-4比值显示,随着高血压血管病变的进展,血小板活化有增加的趋势。这些结果表明,原发性高血压患者中观察到的血小板功能异常在高血压血管并发症的发生发展中起重要作用。